Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: A phase II trial

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1611-1616

  Hainsworth, J D ^a   Jones, S E ^a   Mennel, R G ^a   Blum, J L ^a   Greco, F A ^a  

^a Sarah Cannon Minnie Pearl Cancer C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029913417     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1611     Document Type: Article

References (21)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
4. Holmes FA, Frye D, Valero V, et al: Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11:60, 1992 (abstr)
5. Kennedy MJ, Armstrong D, Donehower R, et al: The hematologic toxicity of the Taxol-Cytoxan doublet is sequence-dependent. Proc Am Soc Clin Oncol 13:137, 1994 (abstr)
6. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
7. Hainsworth JD, Greco FA: Paclitaxel administered by 1-hour infusion: Preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377-1382, 1994
8. Gianni L, Munzone E, Capri G et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
9. Hainsworth JD, Andrews MB, Johnson DH, et al: Mitoxantrone, fluorouracil, and high-dose leucovorin: An effective, well tolerated regimen for metastatic breast cancer. J Clin Oncol 9:1731-1736, 1991
10. Jones SE, Mennel RG, Brooks B, et al: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 19:1736-1739, 1991
11. Hainsworth JD, Jolivet J, Hopkins LE, et al: A randomized phase II trial of mitoxantrone, 5-FU, and high dose leucovorin (NFL) vs cyclophosphamide, methotrexate, 5-FU (CMF) in the first line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 14:90, 1995 (abstr)
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Shenkenberg TD, Von Hoff DD: Mitoxantrone: A new anti-cancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986
14. Saletan S: Mitoxantrone: An active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev 14:297-303, 1987
15. Hainsworth JD, Raefsky EL, Greco FA: Paclitaxel administered by a 1 hour infusion: A phase I/II trial comparing two schedules. Cancer J Sci Am 1:281-287, 1995
16. Weber BL, Vogel C, Jones S, et al: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995
17. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
18. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
19. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of 2 doses of Taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12:42, 1993 (abstr)
20. Rosenthal CJ, Ibrahim A, Rambhia H, et al: Paclitaxel (Taxol)-mitoxantrone salvage therapy in metastatic carcinoma of the breast - Phase I/II study. Proc Am Soc Clin Oncol 13:92, 1994 (abstr)
21. Paul DM, Garrett AM, Meshad M, et al: A phase II trial of paclitaxel, 5-fluorouracil and leucovorin (TFL) in metastatic breast cancer. Proc Am Soc Clin Oncol 14:140, 1995 (abstr)